AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Targeting B Cells in Prostate Cancer

Detailed Technology Description

This invention features methods to reduce androgen-independent prostate cancer. Currently, the most common way to treat primary non-metastatic prostate cancer entails treatment with anti-androgen drugs. In addition, surgical removal or radioablation are also practiced. While these procedures are effective, a major problem is the re-emergence of androgen independent cancer a few years later. Thus, what are needed are methods to reduce (including delay and/or complete inhibition of) the re-emergence of hormone resistant cancer. The inventors have demonstrated in mouse models that B cells remain in the tumor environment, even after castration. These B cells have been shown to assist in the re-emergence of the tumor. In vitro, the same phenomenon has been observed in 90 percent of the samples obtained from humans with malignant prostate cancer. By removing the B cell population, re-emergence of disease is significantly delayed. To older men (the most likely patient population to get prostate cancer), the delay of several years to re-emergence could be considered significant.

Supplementary Information

Patent Number: US20140086918A1
Application Number: US13982083A
Inventor: Karin, Michael | Ammirante, Massimo | Kuraishy, Ali
Priority Date: 31 Jan 2011
Priority Number: US20140086918A1
Application Date: 26 Aug 2013
Publication Date: 27 Mar 2014
IPC Current: A61K004748 | A61K0031381 | A61K0031437 | A61K003817
US Class: 4241341 | 4241731 | 5140195 | 514292 | 514447
Assignee Applicant: The Regents of the University of California
Title: Methods for Inhibiting Prostate Cancer
Usefulness: Methods for Inhibiting Prostate Cancer
Summary: The method is useful for reducing one or more of growth of castration resistant prostate cancer cells in a tissue and metastasis of Cap cells in a tissue, in a mammalian subject, and reducing androgen-induced growth of prostate epithelial cells in a mammalian subject, preferably a human (claimed). No biological data given.
Novelty: Reducing growth of castration resistant prostate cancer cells in a tissue and metastasis of castration resistant prostate cancer cells in a tissue, in a mammalian subject, comprises, administering a compound to the subject